Form 4: Vir Biotechnology EVP and CMO Sells Shares Under Pre-Arranged Plan and for Tax Obligations

Mark Eisner, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc., sold a total of 10,382 shares of common stock in two separate transactions in July 2025.

Summary

• Mark Eisner, EVP and Chief Medical Officer of Vir Biotechnology, Inc. (VIR), reported two sales of common stock.
• On July 15, 2025, 6,796 shares were sold at a price of $5.4682 per share. This sale was automatic and intended to cover the Issuer's tax withholding and remittance obligation related to the vesting of restricted stock units.
• On July 17, 2025, an additional 3,586 shares were sold at a weighted average price of $5.4738 per share, with prices ranging from $5.41 to $5.53. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Eisner on August 5, 2024.
• Following these transactions, Mark Eisner beneficially owns 104,618 shares of Vir Biotechnology common stock directly.

Sentiment

Score: 5

Explanation: The document reports routine insider stock sales, primarily for tax obligations and under a pre-arranged trading plan, which are neutral events and do not indicate a significant positive or negative sentiment towards the company's performance or outlook.

Positives

• The sale of shares under a Rule 10b5-1 trading plan indicates pre-planned, non-discretionary transactions, enhancing transparency and reducing the perception of opportunistic insider trading.

Negatives

• The sale of shares by an executive, even if pre-planned or for tax purposes, reduces their direct ownership stake, which some investors might view as a slight negative, though it is a common occurrence related to compensation.

Future Outlook

The document, an SEC Form 4, reports past insider transactions and does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Form 4 filing details routine insider stock transactions by an executive at Vir Biotechnology, Inc. Such filings are common across all industries, particularly in biotechnology where executive compensation often includes equity awards that lead to pre-planned sales for liquidity or tax purposes. These transactions do not inherently reflect broader industry trends but are standard disclosures for publicly traded companies.

Stakeholder Impact

• Shareholders: The transactions provide transparency regarding executive stock ownership changes, which is standard information for investors. The sales represent a minor reduction in the executive's direct stake.

Key Dates

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Stock Sale, Executive Compensation, Mark Eisner, 10b5-1 Plan, Restricted Stock Units, Tax Withholding